ADTL-SA1215 is a drug which acts as a sirtuin-3 (SIRT3) activator. It has been researched as a potential therapeutic agent for the treatment of triple negative breast cancer, as well as being used for basic research into the structure and function of the SIRT3 enzyme complex.